Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

Metastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast cancer subtypes. Immune checkpoint inhibitors (ICIs) plus chemotherapy have promising survival benefits. Herein, we report a 51-year-old woman whose metastatic lesions were diagnosed as triple-negative subtype and...

Full description

Bibliographic Details
Main Authors:	Yuxin Ma, Xinhong Shi, Kun Zhao, Shuyi Hu, Yue Shi, Yingying Jiang, Yiling Liu, Lin Lu, Yuting Chang, Fei Zhou, Yingying Dai, Zipeng Wu, Shiyi Li, Zhiying Qian, Xia Xu, Chenchen Li, Bo Shen, Guoren Zhou, Cheng Chen, Xiaohua Wang, Jifeng Feng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Frontiers in Oncology
Subjects:	metastatic triple negative breast cancer (mTNBC) immune checkpoint inhibitors (ICIS) tislelizumab eribulin mesylate case report
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1328844/full

Similar Items

Metastatic triple-negative breast cancer – current treatment strategies in the Nordics: a modified Delphi study
by: Antonis Valachis, et al.
Published: (2025-03-01)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
by: Yuan P, et al.
Published: (2021-02-01)

SCEL regulates switches between pro-survival and apoptosis of the TNF-α/TNFR1/NF-κB/c-FLIP axis to control lung colonization of triple negative breast cancer
by: Shih-Hsuan Chan, et al.
Published: (2023-11-01)

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
by: Min Ho Park, et al.
Published: (2020-12-01)

A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy
by: Ruoxue Cai, et al.
Published: (2023-11-01)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
by: Jin Sun Lee, et al.
Published: (2019-11-01)

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
by: Lan Chen, et al.
Published: (2024-05-01)

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
by: Puhalla S, et al.
Published: (2016-12-01)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
by: Tsutomu Iwasa, et al.
Published: (2019-10-01)

Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: a case report and literature review
by: Haishan Wei, et al.
Published: (2024-01-01)

Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
by: Liman Huo, et al.
Published: (2023-10-01)

Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
by: Dingwei Ye, et al.
Published: (2023-03-01)

Eribulin mesylate exerts antitumor effects via CD103
by: Kazumasa Oya, et al.
Published: (2023-12-01)

Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice
by: Takahiro Ishizaka, et al.
Published: (2023-06-01)

Neoadjuvant tislelizumab combination chemotherapy for advanced penile cancer: A case report
by: Wei-Chao Dou, et al.
Published: (2022-03-01)

Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model
by: Shyambabu Chaurasiya, et al.
Published: (2020-01-01)

Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma
by: WEI Zongjie, et al.
Published: (2022-07-01)

Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment
by: Wataru Goto, et al.
Published: (2020-12-01)

Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study
by: Yushan Zhao, et al.
Published: (2024-10-01)

Case report: Preliminary response to tislelizumab plus S-1 in patients with metastatic gallbladder carcinoma: A report of five cases and a literature review
by: Yuzhu Zhang, et al.
Published: (2023-03-01)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
by: Dongchu Zhou, et al.
Published: (2022-08-01)

Preliminary response to Tislelizumab plus chemotherapy drugs in patient with periampullary carcinoma: a report of one case and a literature review
by: Chuanyun Tang, et al.
Published: (2024-07-01)

Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma
by: Kang-shuai Li, et al.
Published: (2024-11-01)

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer
by: Wei Wen, et al.
Published: (2019-08-01)

Tislelizumab: An effective anti-PD-1 antibody for the treatment of advanced basal cell carcinoma of the prostate
by: Hua Jiang
Published: (2024-11-01)

Tislelizumab plus chemotherapy in metastatic extramammary Paget disease after surgery: a case report
by: Dongxing Wang, et al.
Published: (2024-10-01)

Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors
by: LUO Xiangchong, et al.
Published: (2022-07-01)

Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers
by: Xiaojing Zheng, et al.
Published: (2023-02-01)

Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
by: Pingyu Chen, et al.
Published: (2024-05-01)

Tacrolimus and mycophenolate mofetil in corticosteroid-resistant hepatitis secondary to tislelizumab: a case report
by: Chang Jiang, et al.
Published: (2025-02-01)

A real‐world study of immune checkpoint inhibitors in advanced triple‐negative breast cancer
by: Zheng Zhang, et al.
Published: (2023-06-01)

Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China
by: Xiaoyu Zhang, et al.
Published: (2024-07-01)

Dramatic response of advanced pulmonary sarcomatoid carcinoma to tislelizumab combined with anlotinib: a case report
by: Ranran Li, et al.
Published: (2025-02-01)

Case report: Fatal hemoptysis after effective treatment with tislelizumab and anlotinib in pulmonary sarcomatoid carcinoma
by: Chen-Wei Pu, et al.
Published: (2024-09-01)

Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy
by: Meng Yang, et al.
Published: (2024-02-01)

Tislelizumab combined with sunitinib in the treatment of metastatic clear cell renal cell carcinoma with renal venous tumor thrombus: A case report and literature review
by: Zhixiang Gao, et al.
Published: (2024-05-01)

Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer
by: Alice Ilari, et al.
Published: (2024-01-01)

Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: A retrospective study
by: Jiaqi He, et al.
Published: (2024-10-01)

Treatment of Metastatic Primary Extramammary Paget Disease With Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature
by: Xin Yin, et al.
Published: (2022-05-01)

Exfoliative esophagitis secondary to tislelizumab: a case report
by: Mingxing Wang, et al.
Published: (2024-11-01)